NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Exclusion Criteria

• •1. other types of tumors; If the patient has a previous history of malignant tumor, the disease-free time of the patient needs \> for 5 years.
• •2. received major surgery, conventional chemotherapy, large-area radiotherapy, immune therapy or any biological anti-tumor therapy within 4 weeks before enrollment;
• •3. allergic to ingredients in this trial;
• •4. common terminology criteria for adverse events not return to under 2 level from previous surgery or treatment-related adverse reactions;
• •5. poorly managed hypertension (systolic blood pressure \>160 mmHg and / or diastolic blood pressure \> 90 mmHg) or clinically serious (for example, active) cerebrovascular diseases such as cerebrovascular incident (within 6 months prior to signing the informed consent), myocardial infarction (within 6 months prior to signing the informed consent), unstable angina, grade II or above heart failure according to New York Heart Association Grading Congestive, or severe arrhythmia can not be controlled by medication or has a potential impact on the study; with consecutive three times of obvious abnormality on electrocardiogram or average QT corrected interval ≥450 millisecond;
• •6. combined with other serious organic and mental disorders;
• •7. serious or active bacteria, viral or fungal infections that require systemic treatment;
• •8. with autoimmune diseases: such as a history of inflammatory bowel disease or other autoimmune diseases determined by the investigator as unsuitable for the study (e.g. systemic lupus erythematosus,vasculitis, invasive pulmonary disease);
• •9. within 4 weeks prior the infusion, received chronic systemic steroid cortisone, hydroxyurea, immunomodulatory treatment (for example: Interleukin 2, alpha or gamma interferon, granulocyte colony stimulating factor, mammalian target of rapamycin inhibitors, cyclosporine, Thymosin etc);
• •10. with organ transplantation, autologous/allogeneic stem cell transplantation and renal replacement therapy;
• •11. with uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease, or liver failure;
• •12. alcohol and / or drug abuse;
• •13. pregnant or lactating women;
• •14. with any medical condition or disease determined by the investigators that may be detrimental to this trial;
• •15. without legal capacity / limited behavior.
• •16. receive any other gene therapy products before study